Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

HIV/AIDS Vaccine Scholars Program (K01)

Key Dates: 
  • Posted Date: November 2, 2015
  • Open Date (Earliest Submission Date): December 11, 2015
  • Letter of Intent Due Date(s): Not Applicable
  • Application Due Date(s): Not Applicable
  • AIDS Application Due Date(s): January 11, 2016; January 11, 2017 and January 11, 2018, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: March 2016, March 2017 and March 2018
  • Advisory Council Review: May 2016, May 2017 and May 2018
  • Earliest Start Date: July 2016, July 2017 and July 2018
Purpose: 

The purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their degree or residency training. Research and mentorship must be in the field of HIV/AIDS vaccine development, using nonhuman primates (NHPs) as pre-clinical models. These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both development of NHP vaccine models and in translation of the results of investigations performed in NHPs to work in humans. The expectation is through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This funding initiative addresses two objectives of the FY 2016 National Institutes of Health Trans-NIH Plan for HIV-Related Research: 1) To explore new HIV vaccine approaches, and 2) To develop opportunities for new investigators in the HIV vaccine field, enabling them to translate promising preclinical vaccine studies in NHPs into human clinical trials.

Expiration Date: 
Friday, January 12, 2018
Announcement Number: 
PAR-16-028